@misc{oai:repo.qst.go.jp:00063850,
 author = {Hasegawa, Azusa and Mizoe, Junetsu and Jingu, Keiichi and Bessho, Hiroki and Morikawa, Takamichi and Kamada, Tadashi and Tsujii, Hirohiko and 長谷川 安都佐 and 溝江 純悦 and 神宮 啓一 and 別所 央城 and 森川 貴迪 and 鎌田 正 and 辻井 博彦},
 month = {Mar},
 note = {1. Skull Base and Paracervical Tumors
To estimate the toxicity and efficacy of the clinical trials for patients with skull base and paracervical tumors treated with carbon ion radiotherapy.
A phase I/II dose escalation study for skull base and paracervical tumor was initiated in April 1997. The phase I/II dose escalation trial was performed up to the fourth-stage dose level. From April 2004, a phase II clinical trial was initiated under the Highly Advanced Medical Technology scheme with an irradiation schedule of60.8 GyE in 16 fractions over four weeks.
At the time of analysis, there was no evidence of any serious acute or late reactions in skull base and paracervical tumors. For skull base and paracervical tumor, the carbon ion dose in excess of 57.6 GyE improves local control.
2. Head-and-Neck Tumors
To evaluate the efficacy of carbon ion radiotherapy for malignant head-and-neck tumors.
Between April 1997 and August 2009, 363 cases with locally advanced, histologically proven, and new or recurrent malignant tumors of the head-and-neck were treated with carbon ions. Treatment dose was 64.0 GyE in 16 fractions over 4 weeks (or 57.6 GyE when a wide area of skin was included in the target volume).
There were no acute reactions worse than grade 3 and no late toxicities worse than grade 2. The five-year local control and overall survival rates were 73% and 53%, respectively. But the five- year local control rate was 24% for bone and soft tissue sarcomas, and the five-year overall survival rate was 37% for malignant melanomas.
Carbon ion radiotherapy for malignant head-and-neck tumors can be described as presenting no clinical problems. Although local control of carbon ion radiotherapy was promising for malignant head-and-neck tumor excluding sarcoma, the survival rate was not commensurate with the favorable local control rate of malignant melanoma. On the basis of the results of the analysis, this part of the study was divided into two additional protocols, one for bone and soft tissue sarcomas and another for mucosal malignant melanomas., NIRS-CNAO Joint Symposium},
 title = {Carbon Ion Radiotherapy for Skull Base and Head-and-Neck Tumors},
 year = {2010}
}